Literature DB >> 33347953

Clinical utility of the MAFLD definition.

Kenneth I Zheng1, Dan-Qin Sun2, Yi Jin3, Pei-Wu Zhu4, Ming-Hua Zheng5.   

Abstract

Year:  2020        PMID: 33347953     DOI: 10.1016/j.jhep.2020.12.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  10 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

2.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.

Authors:  Ting-Yao Wang; Jacob George; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

3.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.

Authors:  Lei Miao; Li Yang; Li-Sha Guo; Qiang-Qiang Shi; Teng-Fei Zhou; Yang Chen; Huai Zhang; Hui Cai; Zhi-Wei Xu; Shuan-Ying Yang; Hai Lin; Zhe Cheng; Ming-Yang Zhu; Xu Nan; Shuai Huang; Ya-Wen Zheng; Giovanni Targher; Christopher D Byrne; Yu-Ping Li; Ming-Hua Zheng; Cheng-Shui Chen
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 4.  Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?

Authors:  Jalpa Devi; Aimun Raees; Amna Subhan Butt
Journal:  World J Hepatol       Date:  2022-01-27

5.  Metabolic-associated Fatty Liver Disease.

Authors:  Ming-Hua Zheng
Journal:  J Clin Transl Hepatol       Date:  2021-11-09

6.  Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus.

Authors:  Qiuping Yang; Leisheng Zhang; Qian Li; Man Gu; Qiu Qu; Xinglong Yang; Qinghua Yi; Kunli Gu; Linli Kuang; Mei Hao; Jing Xu; Hongju Yang
Journal:  BMC Microbiol       Date:  2022-04-15       Impact factor: 4.465

7.  SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface.

Authors:  Nan Zhao; Xiaoxun Zhang; Jingjing Ding; Qiong Pan; Ming-Hua Zheng; Wen-Yue Liu; Gang Luo; Jiaquan Qu; Mingqiao Li; Ling Li; Ying Cheng; Ying Peng; Qiaoling Xie; Qinglin Wei; Qiao Li; Lingyun Zou; Xinshou Ouyang; Shi-Ying Cai; James L Boyer; Jin Chai
Journal:  JCI Insight       Date:  2022-08-08

Review 8.  Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Authors:  Wah-Kheong Chan; Soek-Siam Tan; Siew-Pheng Chan; Yeong-Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva; Khean-Lee Goh; Anis Safura Ramli; Feisul Mustapha; Nik Ritza Kosai; Raja Affendi Raja Ali
Journal:  J Gastroenterol Hepatol       Date:  2022-02-08       Impact factor: 4.369

9.  MAFLD in Obese Children: A Challenging Definition.

Authors:  Anna Di Sessa; Stefano Guarino; Giuseppina Rosaria Umano; Mattia Arenella; Salvatore Alfiero; Gaetano Quaranta; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  Children (Basel)       Date:  2021-03-23

10.  MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.

Authors:  Jiaofeng Huang; Wenjuan Xue; Mingfang Wang; Yinlian Wu; Medha Singh; Yueyong Zhu; Rahul Kumar; Su Lin
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-27       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.